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Streptococcus agalactiae (group B streptococci (GBS)) is an important infections agent in newborns associated with maternal
vaginal colonization. Intrapartum antibiotic prophylaxis in GBS-colonized pregnant women has led to a significant reduction in the
incidence of early neonatal infection in various geographic regions. However, this strategy may lead to resistance selecting among
GBS, indicating the need for new alternatives to prevent bacterial transmission and even to treat GBS infections.This study reported
for the first time the effect of eugenol on GBS isolated from colonized women, alone and in combination with silver nanoparticles
produced by Fusarium oxysporum (AgNPbio). Eugenol showed a bactericidal effect against planktonic cells of all GBS strains,
and this effect appeared to be time-dependent as judged by the time-kill curves and viability analysis. Combination of eugenol
with AgNPbio resulted in a strong synergistic activity, significantly reducing the minimum inhibitory concentration values of both
compounds. Scanning and transmission electron microscopy revealed fragmented cells and changes in bacterial morphology after
incubation with eugenol. In addition, eugenol inhibited the viability of sessile cells during biofilm formation and inmature biofilms.
These results indicate the potential of eugenol as an alternative for controlling GBS infections.
1. Introduction
Streptococcus agalactiae (Group B Streptococcus (GBS)) is an
important cause of invasive diseases, mainly in newborns,
pregnant women, and elderly individuals [1, 2]. Neonatal
early onset diseases, which are characterized by sepsis, pneu-
monia, or meningitis, are strongly associated with maternal
vaginal colonization and may occur vertically by aspiration
of infected amniotic fluid or during passage through the birth
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Table 1: Phenotypic and genotypic characteristics and antibacterial susceptibility profile of eugenol for planktonic and sessile cells of
Streptococcus agalactiae.
GBS
strains
MLVA genotypesa Capsular typesa E (𝜇g/mL) DA (𝜇g/mL)
Antimicrobial resistance
genesa Eugenol (%)
MICb MICb/MBCc SMIC
100
d SMIC
50
e
50 8 Ia 0.25 0.25 — 0.5 0.25 0.09
72 5 III 0.125 0.25 — 0.125 0.25 0.06
80 6 V 0.25 0.125 — 0.25 0.125 0.05
89 13 Ia 0.25 0.125 — 0.25 0.25 0.09
115 7 V >1024 1024 ermB 0.125 0.5 0.02
121 8 Ia 16 0.125 mefA/E 0.125 0.5 0.25
ATCC 13813 — — 0.125 0.125 — 0.25 0.06 0.04
aThe genetic diversity, the capsular type, and the resistance genes were previously determined byOtaguiri et al. [11]. bMinimum inhibitory concentration (MIC)
of the compound which resulted in total inhibition of visible planktonic cell growth defined according to CLSI (2012) [31] guidelines by broth microdilution
assays. cMinimum bactericidal concentration (MBC) of the eugenol. dSessileMIC (SMIC) of the eugenol which resulted in total reduction inmetabolic activity
of sessile cells during biofilm formation, using theXTT-reduction assay, after 24 h. eSMICof the eugenolwhich resulted in 50%of reduction inmetabolic activity
of sessile cells from mature biofilm (24 h), using the XTT-reduction assay. MLVA: multiple locus variable number of tandem repeat analysis; E: erythromycin;
DA: clindamycin.
canal [3]. It is estimated that 10–37% of pregnant women are
colonized with GBS, and in the absence of any intervention,
30–70% of newborns become colonized, of which about 1–3%
develop invasive diseases with high mortality rates [3, 4].
The active prevention strategy for GBS neonatal infec-
tions based on bacterial screening and intrapartum antibiotic
prophylaxis (IAP) has led to a significant reduction in the
incidence of early neonatal infection in various regions of the
world. Current IAP consists of intravenous administration
of beta-lactams (penicillin or ampicillin) to GBS-colonized
pregnant woman for 4 h before delivery. Erythromycin, clin-
damycin, and vancomycin are the agents recommended in
cases of colonization during pregnancy with beta-lactam-
resistant GBS or beta-lactam allergy [4].
In general, GBS isolates have been shown to be sensitive
to beta-lactams [5–7]. However, GBS isolates with reduced
susceptibility and even resistance to beta-lactam agents have
been reported in recent years [8, 9]. Moreover, resistance
to erythromycin and clindamycin among GBS isolates has
emerged in different regions of the world, with rates ranging
from 14.5% to 70% and 8.2% to 70% for erythromycin and
clindamycin, respectively [10–12].
Besides the emergence of GBS resistant to current antibi-
otics, the development of vaccines against GBS is still in
progress, indicating that new safe and effective alternatives
should be developed to prevent the transmission of this bac-
terium. Several authors have described the antibacterial activ-
ity of natural products against GBS [13–15], indicating their
potential as alternatives for IAP, reducing the risk of develop-
ment of resistance to commercially available antibiotics.
Eugenol, a major constituent of essential oils extracted
from various plants, has been widely studied due to its
medicinal properties, such as the following: antibacterial
[16–18], antifungal [19], antiviral [20], antileishmanial [21],
antioxidant [22], anticarcinogenic [23], and analgesic and
anti-inflammatory [24]. Similarly, silver nanoparticles have
been extensively investigated because of their antimicrobial
properties alone [25, 26] or in combination with other
compounds [27–29].
In this study, we evaluated the antibacterial effect of the
phenylpropanoid eugenol on planktonic cells and biofilm
of GBS isolated from colonized women, including those
exhibiting resistance to erythromycin and clindamycin and
its synergistic interaction with silver nanoparticles produced
by Fusarium oxysporum (AgNPbio).
2. Material and Methods
2.1. Bacteria and Growth Conditions. Six nonduplicates
strains of Streptococcus agalactiae (GBS) recovered from
vaginal-rectal swabs of colonized women were taken from
the bacterial collection of the Laboratory of Clinical Micro-
biology of University Hospital of Londrina, Parana´, Brazil.
Bacterial strains were included according to phenotypic and
genotypic characteristics [11] (Table 1). Bacteria were kept
at −20∘C in tryptic soy broth (TSB, Oxoid) containing
20% glycerol and 5% sheep blood. The reference strain S.
agalactiae ATCC 13813 (kindly donated by FIOCRUZ, Rio
de Janeiro, Brazil) was also included in this study. Bacteria
were grown in TSB, pH 6.5, at 37∘C for 24 h before the assays.
The study protocol was approved by the Ethics Committee of
the Universidade Estadual de Londrina (document 186/09-
CEP/UEL). Written informed consent was obtained from
the patients for the publication of this report and any
accompanying images.
2.2. Eugenol and Biologically Synthesized Silver Nanoparticles.
A stock solution of 10% eugenol (SSWhite, Brazil) was
prepared in TSB, pH 6.5, containing 10% (v/v) dimethyl sul-
foxide (DMSO; Sigma Chemical Co., USA). The DMSO final
concentration in the assays did not exceed 1.0%. Biological
silver nanoparticles (AgNPbio) were obtained after AgNO
3
reduction by F. oxysporum as previously described [30].
Briefly, F. oxysporum was cultured in broth medium contain-
ing 0.5% yeast extract at 28∘C for 6 days. The fungal biomass
was filtered, added (approximately 10 g) to 100mL of distilled
water, and incubated at 28∘C for 72 h. A fungal-free solution
was obtained by filtration and mixed with 1.0mM AgNO
3
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and the mixture was kept at 28∘C for 28 h. AgNPbio were
purified and characterized by scanning electron microscopy
and energy-dispersive spectroscopy.
2.3. Antibacterial Activity of Eugenol against Planktonic Cells.
The minimal inhibitory concentration (MIC) of eugenol
was determined by broth microdilution method according
to the Clinical and Laboratory Standards Institute [31],
with modifications. Twofold serial dilutions of eugenol (1–
0.015%) in TSB were prepared in sterile polystyrene 96-
well plates (Techno Plastic Products, Switzerland). Wells
contained medium alone or medium plus 1% DMSO and
untreated planktonic cells, and medium alone served as
growth and sterility controls. After 24 h incubation, optical
density was measured at 600 nm with a microtiter plate
reader (Synergy HT, Biotek) and MIC was determined at
total inhibition of growth after 24 h incubation compared
to untreated planktonic cells [32]. MICs for erythromycin
and clindamycin were also determined as described above,
and Streptococcus pneumoniae ATCC 49619 was used as
the quality control. To determine the minimal bactericidal
concentration (MBC), the content from the wells (10 𝜇L)
showing no growth was transferred to plates with tryptic soy
agar (TSA, Oxoid) containing 5% sheep blood and incubated
at 37∘C for 24 h. MBC was defined as 100% decrease in
colony forming units (CFU) compared to untreated bacteria.
All assays were carried out in triplicate on two different
occasions.
2.4. Time-Kill Curves. For time-kill curve analysis, plank-
tonic cells of GBS 89, GBS 121, and S. agalactiae ATCC
13813 (1–5 × 105 CFU/mL) were incubated in TSB containing
MIC levels of eugenol. At determined time points (0, 1, 2,
4, 6, 8, 10, and 24 h), aliquots were aseptically transferred
to TSA plus 5% sheep blood plates and the CFU counts
were determined after incubation at 37∘C for 24 h. The
bacterial viability of eugenol-treated GBS was also evaluated,
using LIVE/DEAD BacLight staining kit (Molecular Probes,
Invitrogen) according to the manufactures’ recommenda-
tions. This assay is based on the detection of two nucleic
acid fluorescent stains. Green-fluorescent SYTO 9 labels live
and dead bacteria, whereas the red fluorescent propidium
iodide selectively labels bacteria with permeable (damaged)
membranes. Bacterial cells were placed on a glass coverslip
and analyzed by fluorescence microscopy (LEICA DM2000).
All assays were carried out in triplicate on three different
occasions.
2.5. Antibacterial Activity of Eugenol against Biofilms. Bio-
films of GBS strains and S. agalactiae ATCC 13813 were
formedonpolystyrene surface of flat-bottomed96-wellmicrot-
it-er plates (Techno Plastic Products, Switzerland) in a static
model at 37∘C according to Borges et al. [33]. Briefly, bacterial
cells were grown in TSB at 37∘C for 18 h, harvested by
centrifugation, and washed with sterile 0.15M phosphate-
buffered saline (PBS), pH 7.2, and the cell density was
adjusted to 1.0 × 108 CFU/mL in the same medium. Twofold
serial dilutions of eugenol (2–0.03%) were prepared in TSB.
For analysis of eugenol effect during biofilm formation,
a 20𝜇L aliquot of each cell suspension was transferred to
each well containing 180 𝜇L of TSB with different concen-
trations of eugenol, and the plates were incubated for 24 h.
For analysis of eugenol effect on mature biofilm, 20𝜇L
of each cell suspension was added to each well contain-
ing 180 𝜇L of TSB. After 24 h of biofilm formation, the
medium was aspirated off and each well was washed with
sterile PBS. A 200 𝜇L aliquot of TSB containing different
concentrations of eugenol was added and the plates were
incubated for another 24 h. Controls included eugenol-
free wells and biofilm-free wells. Sessile (biofilm) mini-
mum inhibitory concentrations were determined at 50 and
100% inhibition (SMIC) compared to eugenol-free control
wells using the 2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-5-
[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT)-
reduction assay [34]. A 200 𝜇L aliquot of XTT-menadione
[0.5mg/mL XTT, 1mM menadione (Sigma Chemical Co.,
USA)] was added to each well, and the plates were incubated
in the dark at 37∘C for 90min, after which the optical
density was measured at 490 nm with a microtiter plate
reader (Synergy HT, Biotek). Experiments were carried out
in quintuplicate on two different occasions.
2.6. Electron Microscopy Analysis. Planktonic cells treated
with MIC levels of eugenol for 5 h were fixed for 2 h at
room temperature with 2.5% glutaraldehyde in 0.1M sodium
cacodylate buffer, pH 7.2. For scanning electron microscopy
(SEM), postfixed cells were dehydrated with a series of
ethanol washes (15, 30, 50, 70, 80, 90, 95, and 100%), critical-
point dried in CO
2
, coated with gold, and examined with
a SHIMADZU SS-550 scanning electron microscope. For
transmission electron microscopy (TEM), postfixation was
carried out in 1% osmium tetroxide in cacodylate buffer
containing 0.8% potassium ferrocyanide and 5mM CaCl
2
at
room temperature for 1 h. The cells were dehydrated in
acetone and embedded in Epon resin. Ultrathin sections were
stained with uranyl acetate and lead citrate and examined
with a Zeiss EM900 electron microscope.
2.7. Analysis of the Combinations of Eugenol and AgNPbio.
The effect of eugenol combined with AgNPbio on planktonic
cells of GBS was assessed by checkerboard method in 96-well
microtiter plates, as previously described [35]. Twofold serial
dilutions of the compounds were prepared in TSB, and the
final concentrations of eugenol and AgNPbio ranged from 1
to 0.015% and 500 to 0.49 𝜇M, respectively. Bacteria (1.0 ×
105 cells) were grown with eugenol or AgNPbio individually
and in combinations at 37∘C for 24 h. The interactions of the
two compounds were analyzed by the fractional inhibitory
concentration index (FICI), which was defined as the sum
of FICeugenol and FICAgNPbio. FIC of the material is the
concentration that kills when being used in combinationwith
another divided by the concentration that has same effect
when used individually [35].
2.8. Statistical Analysis. The results were evaluated by one-
way ANOVA using the GRAPHPAD PRISM version 5.0
(GRAPHPAD Software, San Diego, CA). 𝑃 < 0.05 was
considered significant.
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Figure 1: Effect of eugenol on growth (a–c) and viability (d-e) of Streptococcus agalactiae. Time-kill curves of GBS 89 (a), GBS 121 (b), and
S. agalactiae ATCC 13813 (c) strains: bacteria were incubated with eugenol at MIC for 24 h at 37∘C and the CFU counts were determined at
specified time points. Viability of the cells was determined with live-dead staining and GBSs with intact membranes were green-fluorescent
(d), whereas eugenol-treated GBSs (at MIC) with damaged membranes were red-fluorescent (e). Representative images are shown. Bar =
5 𝜇m.
3. Results
3.1. Antibacterial Activity of Eugenol against Planktonic
Cells. Eugenol inhibited the planktonic growth of all GBS
strains, including those resistant to erythromycin and/or
clindamycin. MIC and MBC values were exactly at the
same concentrations for all GBS strains analyzed in this
study. The mean MIC/MBC value was 0.23 ± 0.13% ranging
from 0.125 to 0.5% (Table 1). To evaluate the killing kinetics
of eugenol against GBS, survival of planktonic cells from
GBS 89, GBS 121, and reference strain was assessed during
24 h in the presence of the phenylpropanoid at MIC. As
shown in Figure 1, a time-dependent bactericidal effect was
observed for all strains. The presence of eugenol at MIC
reduced the planktonic cell population approximately by 1 to
2 log
10
CFU/mL (𝑃 < 0.05) after one hour of incubation. No
colony forming units (Figures 1(a), 1(b), and 1(c)) or cellular
viability (Figures 1(d) and 1(e)) was detected after 2, 4, and
10 h of incubation in the presence of eugenol for GBS 89, GBS
121, or reference strain. At the specified time, all eugenol-
treated GBSs were red-fluorescent, reflecting dead bacteria
with damaged membranes, in contrast to green-fluorescent
untreated cells.
The combination of eugenol with AgNPbio significantly
reduced (𝑃 < 0.05) the MIC value of both compounds,
and the calculated FICI indicated a synergistic effect between
them against all GBS strains (Table 2). AgNPbio alone at
125 𝜇M inhibited the growth of all GBS strains. When
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Table 2: In vitro synergistic effect of eugenol and biological silver nanoparticles on Streptococcus agalactiae growth.
GBS strains MIC
a
FICId Effect
Eugenolb (%) AgNPbioc (𝜇M) Eugenol/AgNPbio
50 0.5 125 0.06/15.62 0.25 Synergism
72 0.125 125 0.03/31.25 0.5 Synergism
80 0.25 125 0.06/0.49 0.25 Synergism
89 0.25 125 0.03/7.8 0.19 Synergism
115 0.25 125 0.03/31.25 0.38 Synergism
121 0.125 125 0.03/3.9 0.281 Synergism
ATCC 13813 0.25 125 0.03/15.62 0.25 Synergism
aMIC: minimum inhibitory concentration. bMIC of eugenol used alone. cMIC of silver nanoparticle used alone. dFICI: fractional inhibitory concentrations
index were calculated according to Yadav et al. [35] and classified as follows: synergistic if FIC ≤0.5, additive if FIC >0.5 and ≤1.0, indifferent if FIC >1.0 and
≤2.0, and antagonistic if FIC >2.0.
the two compounds were combined, the MIC values of
eugenol and AgNPbio decreased 4- to 8-fold and 4- to 256-
fold, respectively.
3.2. Morphological and Ultrastructural Alterations in Eugenol-
Treated Planktonic Cells. SEM images showed untreated con-
trol cells with typical morphology arranged in an organized
manner (Figure 2(a)). In contrast, the incubation of GBS
planktonic cells with an inhibitory concentration of eugenol
for 5 h led to cell lysis resulting in leakage of cytoplasmic
contents (Figure 2(b)). Likewise, TEM imaging of control
cells showed an intact cell wall with regular electron density
(Figure 2(c)) and treated cells displaying various alterations
such as changes in bacterium morphology; disruption of cell
wall (arrow), corroborating the SEM results; and decrease in
electron density (Figure 2(d)).
3.3. Antibacterial Activity of Eugenol in Biofilms. Eugenol
inhibited biofilm formation of GBS, and nometabolic activity
was detected at concentrations ranging from 0.06 to 0.5%,
where these values were considered, SMIC
100
(Table 1). In
addition, eugenol decreased significantly the viability of
mature (24 h) biofilm at concentrations ranging from 0.03
to 2%, with SMIC
50
ranging from 0.02 to 0.25% (Table 1).
However, except for the reference strain, no total inhibition
was observed at the highest concentration tested in this study.
At 2% eugenol, reduction in metabolic activity ranged from
60 to 90% for the other GBS strains, where GBS 121 biofilm
was the least susceptible.
4. Discussion
Eugenol is a remarkably versatile molecule, which can be
incorporated as a functional compound in various products
applied not only in the pharmaceutical industry but also in
the agricultural, food, and cosmetic industries as well [36].
In this study, the bactericidal activity of eugenol against
human isolates of S. agalactiae, including those exhibiting
different mechanisms of resistance to erythromycin and/or
clindamycin, is reported for the first time. The antibacterial
activity of eugenol against planktonic cells of different species
of the genus Streptococcus has been previously reported [35,
37–39]. Baskaran et al. [37] reported the bactericidal activity
of eugenol against planktonic cells of five agents of bovine
mastitis, including S. agalactiae, whose MIC and MBC were
0.4 and 0.8%, respectively.
The bactericidal effect of eugenol on S. agalactiae seems
to be dependent on changes in the cell envelope, as judged
by alterations in themorphology and ultrastructure observed
in treated cells. In fact, other authors reported that eugenol
induces cell lysis through protein and lipid leakage, leading
to extrusion of cytoplasmic content in variousGram-negative
andGram-positive bacteria, including Streptococcus pyogenes
[17, 35, 38]. In addition, eugenol is capable of inhibiting
the membrane-bound ATPase activity of Escherichia coli and
Listeria monocytogenes [40].
In this study, silver nanoparticles synthesized by an
ecofriendly method using the filamentous fungus F. oxys-
porum showed inhibitory activity against planktonic cells
of all GBS strains. Moreover, the synergistic antibacterial
interaction of AgNPbio with eugenol against GBS is reported
for the first time. Metallic nanoparticles have been widely
studied because of their broad spectrum antimicrobial effect,
even at low concentrations [25–28]. In addition, the combi-
nation of these nanoparticles with several compounds has
shown potent antimicrobial activity in different microbial
species, including those displaying resistance to conventional
antibiotics [26–29]. Accordingly, additive or synergistic effect
of essential oil component cinnamaldehyde with chemically
synthesized silver nanoparticles against Gram-positive and
Gram-negative bacteria has been reported elsewhere [29].
Current antibacterial agents have limited efficacy on
biofilms. Sessile (adhered) bacteria in these communities
have different physiological characteristics compared to free-
floating planktonic cells. Clinically, these features can result
in protection against the host immune system and less sus-
ceptibility to antimicrobial agents, contributing to persistent
infections and difficult treatment [41]. Biofilms are also
established during host colonization, enabling the bacteria to
withstand removal by mechanical processes [42]. Except for
S. agalactiae, the antibiofilm activity of eugenol for various
bacterial species has been reported elsewhere [35, 43]. In this
study, eugenol also exhibited an antibacterial activity against
biofilms of S. agalactiae, showing the ability to inhibit its
formation as well as the viability of mature biofilm, under
in vitro conditions. Similarly, Yadav et al. [35] reported the
inhibitory effect of eugenol against biofilms of S. pneumoniae.
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Figure 2: Scanning electron microscopy (a and b) and transmission electron microscopy images (c and d) of the effect of eugenol on
Streptococcus agalactiaeATCC 13813. Untreated cells (a and c) and treated cells with eugenol 0.25% for 5 h (b and d). Bar: (a and b) = 1 𝜇m, (c
and d) = 200 nm.
Furthermore, Adil et al. [44] described that Streptococcus
mutans incubated in the presence of subinhibitory concentra-
tions of eugenol showed decreased expression of genes related
to biofilm formation.
A limitation of this study, which may reduce the gener-
alization of the results, is the number of GBS strains. Despite
this limitation, the results presented here showed the antibac-
terial activity of eugenol against S. agalactiae, alone or in
combinationwithAgNPbio, opening a promising strategy for
application in IAP for women colonized with this bacterium.
In this sense, a variety of evidence supports the application of
eugenol in human healthcare. The addition of eugenol and
other essential oils in animal feed reduced the Clostridium
perfringens load in the gut of broiler chickens. Although this
bacterium can be a harmless intestinal inhabitant of chickens,
it is the leading agent of necrotic enteritis in these hosts [45].
Topical application of eugenol on teeth reduced the incidence
and severity of carious lesions caused by S.mutans in rats [39].
Preliminary in vivo studies have shown the safety and efficacy
of topical use of eugenol in combination with thymol in the
treatment of bacterial vaginosis and vaginal candidiasis [46].
The incorporation of eugenol in polymeric material has been
shown to reduce the biofilm formation on surfaces [43].
5. Conclusion
The results obtained in this study demonstrated the bacterici-
dal activity of eugenol and its synergistic effect with AgNPbio
against planktonic cells of S. agalactiae. Furthermore, this
compound inhibited biofilm formation and viability of
mature biofilm formed on polystyrene.
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